<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03476421</url>
  </required_header>
  <id_info>
    <org_study_id>HCC R1vasc</org_study_id>
    <nct_id>NCT03476421</nct_id>
  </id_info>
  <brief_title>R1vascular Hepatectomy for HCC Patients</brief_title>
  <official_title>Is R1 Vascular Hepatectomy for Hepatocellular Carcinoma Oncologically Adequate?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Humanitas Clinical and Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Humanitas Clinical and Research Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Since the previous decade, the authors introduced the R1 vascular (R1vasc) resection for the
      treatment of hepatocellular carcinoma (HCC), and colorectal liver metastases (Torzilli et al.
      J Am Coll Surg 2005; Viganò et al. Ann Surg Oncol 2016; Torzilli et al. Surgery 2017).
      However, oncological reliability of tumor exposure in surgery for HCC remains controversial
      since it has never been validated. The aim of the study is to determine the oncological
      adequacy of R1vasc hepatectomy in patients with HCC.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A prospective cohort of patients who underwent hepatectomy for HCC between January 2005 and
      December 2015 is reviewed. The following definitions are adopted: R0 is any resection with at
      least 1 mm of negative margin; R1vasc is any resection with tumor exposure due to the
      detachment from major intrahepatic vessel (1st/2nd order glissonean pedicles and hepatic vein
      at caval confluence); R1-parenchymal (R1par) is any resection with tumor exposure at
      parenchymal margin.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2005</start_date>
  <completion_date type="Actual">January 1, 2018</completion_date>
  <primary_completion_date type="Actual">December 31, 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Rates of local recurrence</measure>
    <time_frame>From date of surgery until the date of first documented progression or date of death from any cause, which ever came first assessed up to 72 months</time_frame>
    <description>Calculation of the local recurrence (cut-edge tumor re-growth) of R0, R1par, and R1vasc, and R1par+R1vasc hepatectomy.</description>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Actual">327</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>R0 hepatectomy</arm_group_label>
    <description>Those HCC patients operated with standard R0 hepatectomy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>R1par hepatectomy</arm_group_label>
    <description>Those HCC patients operated with R1par hepatectomy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>R1vasc hepatectomy</arm_group_label>
    <description>Those HCC patients operated with R1vasc hepatectomy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>R1par+R1vasc hepatectomy</arm_group_label>
    <description>Those HCC patients operated with both R1par and R1vasc hepatectomy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Hepatic resection</intervention_name>
    <description>Surgery of the liver; removal of a part of the liver</description>
    <arm_group_label>R0 hepatectomy</arm_group_label>
    <arm_group_label>R1par hepatectomy</arm_group_label>
    <arm_group_label>R1vasc hepatectomy</arm_group_label>
    <arm_group_label>R1par+R1vasc hepatectomy</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with HCC (hepatocellular carcinoma) who underwent hepatectomy.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  only patients with a primary untreated HCC were included;

          -  complete follow-up data with available computed tomography (CT) and/or magnetic
             resonance imaging (MRI) images showing the first recurrence

        Exclusion Criteria:

          -  patients who underwent vascular resection for direct infiltration of the vessel wall

          -  patients who had radiofrequency ablation in association to surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <results_reference>
    <citation>Torzilli G, Montorsi M, Donadon M, Palmisano A, Del Fabbro D, Gambetti A, Olivari N, Makuuchi M. &quot;Radical but conservative&quot; is the main goal for ultrasonography-guided liver resection: prospective validation of this approach. J Am Coll Surg. 2005 Oct;201(4):517-28.</citation>
    <PMID>16183489</PMID>
  </results_reference>
  <results_reference>
    <citation>Torzilli G, Donadon M, Palmisano A, Marconi M, Procopio F, Botea F, Del Fabbro D, Cappellani A, Montorsi M. Ultrasound guided liver resection: does this approach limit the need for portal vein embolization? Hepatogastroenterology. 2009 Sep-Oct;56(94-95):1483-90.</citation>
    <PMID>19950814</PMID>
  </results_reference>
  <results_reference>
    <citation>Viganò L, Procopio F, Cimino MM, Donadon M, Gatti A, Costa G, Del Fabbro D, Torzilli G. Is Tumor Detachment from Vascular Structures Equivalent to R0 Resection in Surgery for Colorectal Liver Metastases? An Observational Cohort. Ann Surg Oncol. 2016 Apr;23(4):1352-60. doi: 10.1245/s10434-015-5009-y. Epub 2015 Dec 29.</citation>
    <PMID>26714946</PMID>
  </results_reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 15, 2018</study_first_submitted>
  <study_first_submitted_qc>March 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2018</study_first_posted>
  <last_update_submitted>March 22, 2018</last_update_submitted>
  <last_update_submitted_qc>March 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Humanitas Clinical and Research Center</investigator_affiliation>
    <investigator_full_name>Matteo Donadon</investigator_full_name>
    <investigator_title>Assistant professor of surgery, staff surgeon</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

